Pittcon is the world’s leading annual conference and exposition on laboratory science. Pittcon attracts attendees from industry, academia and government from over 90 countries worldwide.

Please join us for Illinois Rare Disease Day on Wednesday, March 4, 2020 at the State House Inn, 101 E Adams St, Springfield, IL 62701 from 9:00am-12:00pm. Join patients, families, caregivers, medical professionals and industry representatives at this important event to discuss with Illinois Legislators the challenges rare disease patients face and learn how you can make a difference in the lives of rare disease patients and their families here in our great state of Illinois. Following the presentations and lunch there will be an opportunity for advocates to visit legislators offices and speak with them and/or their staffers.

Join us to learn about an exciting pilot program by Women In Bio-Chicago in partnership with Horizon Therapeutics. The 3.8 Initiative seeks to increase diversity in the healthcare community in the Chicagoland area and create a forum by which women can safely discuss and address the challenges they face in leadership positions. Please join us to hear the vision behind the program from its co-founders, Holly Copeland, Maryam Saleh, and Dimitra Georganopoulou.

Program

5:30 p.m. – 6:15 p.m. CST – Registration, Networking, Appetizers, Remarks
6:30 p.m. – 7:30 p.m. CST – Panel Discussion and Q&A
7:30 p.m. – 8:00 p.m. CST – Networking

Understanding the Most Important–But Least Understood–Part of Every Tech M&A Process 

Valuation is the most important part of every tech transaction, the key component in determining the net proceeds to shareholders when a transaction closes. Yet the actual process of valuation is not well- understood.

This webinar will discuss the valuation of companies such as WeWork, which had a $47 billion valuation in January 2019 in a private round which decreased dramatically to $8 billion in the Softbank bailout in October 2019. How is it possible for Wall Street to value a company at such a huge differential?

The webinar will address valuation methodologies used by companies on the sell side, including comparable companies, precedent transactions and discounted cash flow as well as the percentage of global market share. The buy-side valuation methods will also be examined, including the buyer’s own internal projections on how much of the sell-side company’s products can be sold by its global sales team.

Finally, the webinar will provide practical tips on how to maximize valuations for private companies on the sell-side.

Participants will also have the opportunity to ask questions during and after the discussion.

After monitoring developments over the past couple hours, discussing it internally, and out of an abundance of caution, we have decided to cancel the March 12 iBIO Happy Hour.

We will be issuing refunds to the attendees who paid for tickets.

I was really looking forward to seeing everyone tomorrow night. There is nothing more I enjoy than hosting events that bring our community together.

We will keep the Guinness cold so stay healthy, wash your hands and I look forward to seeing you at a future iBIO Happy Hour.

Join us at our complimentary webinar on ‘IP Valuation and Mergers & Acquisitions (M&A) with a Focus on BioTech and Life Science’ on Wednesday, 18 March.

Hear from Aon IP experts who will share key insights on areas such as drug formula patents, medical devices (including testing equipment), patents/trade secrets, as well as various risk mitigation tools relating to M&A activities in the biotechnology and life science industry.

The webinar will focus on:
• Management of IP portfolio
• Third-party IP claims
• Key drivers behind the IP valuation
• Mitigation of regulatory and transaction risks of M&A

We invite you to join us for a seminar geared specifically toward drug development professionals. Regis is excited to host guest speaker, Dr. Evan B. Siegel for a special presentation on efficient regulatory strategies.

Enjoy a morning of coffee and chemistry with us at Regis Technologies’ Morton Grove facility.
Limited seating is available. RSVP by March 15 to save your seat.

Abstract
There are many pathways to take in moving discovery data and early drug development data into the clinic. Recognition of the regulatory pathways that will be most efficient, cost-effective, and time-sparing is critical in the choice of partner, consultants and staff as a great idea is brought into the practical world of exploratory and confirmatory patient treatment. This seminar will provide a framework for the types of datasets that will be of most interest and usefulness to regulators, and will present concrete examples of how sparse data can be leveraged towards success for a provisional small molecule or biologic product.

Meet Our Speaker
Dr. Evan B. Siegel founded Ground Zero Pharmaceuticals, Inc. (GZP) in 1999 from his consulting firm, Ground Zero Strategics, Ltd. He currently serves as its President and CEO and is also the Chairman of the Board. Prior to GZP Evan served as Consultant and CEO to OXO Chemie Inc., Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc. (now Interleukin Genetics), and Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., North Carolina. Dr. Siegel has also held regulatory affairs and executive positions at Astra and Syntex and was a Toxicology Reviewer at the US Food and Drug Administration, as well as Supervising Toxicologist and Chief of Special Services at the State of California’s Food and Drug Branch, Department of Health Services.
We are excited to host guest speaker, Dr. Evan B. Siegel for this special presentation.

As the globe grapples with increasing challenges to sustaining “business as usual” in their enterprises, our team of Employment, Employee Benefits, Health and Privacy & Cybersecurity lawyers invite you to join us for important and urgent guidance on a developing pandemic.

Over a ninety minute period, we will cover:

• Developing strategies around remote work facilitation including:responsibilities to quarantined and/or sick employees; work from home arrangements and social distancing; absences from work, paid time off, sick leave; discrimination, harassment and retaliation concerns; the impact on health plans and savings accounts, as well as health and safety considerations.
• Mitigating Privacy and Cybersecurity risk by examining: privacy issues in sharing personal information of employees, guests or customers with third parties, including government agencies, and guidelines for sharing personal  information for COVID-19 response when the data was originally collected for a different purpose. We will also discuss whether, when and how to inform individual that your company has shared their personal information for public health purposes.
• HIPAA compliance considerations including: reporting to public health authorities; informing individuals who may have been in contact with a patient; discussing COVID-19 cases with the media; performing data analytics; and heightened security awareness.

The first in a series of webinars, we will arm you with actionable information to keep your business moving forward and answer your most pressing questions as the situation continues to evolve and change at a rapid pace.

2:00pm G2G’s Webinar: Government Funding

Learn about coronavirus response, BARDA and DoD funding opportunities for all bioscience areas, and how you can prepare for the upcoming MHSRS abstract deadline March 25 and conference in August.

This webinar will provide an overview of how companies can access non-dilutive government funding. It includes updates on the process for accessing funding included in the bipartisan supplemental package passed by Congress to support coronavirus preparedness and response efforts across the country, a look at Department of Defense funding opportunities for innovative technologies to fill military medical gaps, and how to submit an abstract to present your innovations at this year’s Military Health System Research Symposium that will be held in August.

Topics Covered:

• Overview of coronavirus response and government funding
• DoD and other funding for biosciences
• How to submit an abstract to MHSRS
• Case studies and tips for success

If you cannot participate in the webinar and would like to learn how to access non-dilutive federal government funding or to get your innovative technology in front of the DoD, BARDA, HHS, NSF and other government targets, please contact Liz Powell at lpowell@G2Gconsulting.comor (202) 445-4242 or visit www.G2Gconsulting.com.

This year the American College of Cardiology will join with the World Heart Federation to host ACC.20 Together With World Congress of Cardiology (ACC.20/WCC). Here you’ll get the latest science, innovation and practice-changing updates in care, with a special focus on global health.